Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.
According to CRI, the sales value of Lyrica increased by more than 200 times from about CNY 200,000 in 2010 to over 40 million in 2017. Due to Lyrica’s success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.’s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2017, Pfizer’s Lyrica had a market share of approximately 79.8%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer’s Lyrica will continue to dominate the Chinese market from 2018 to 2022 but its market share will decline because of the price competition of China-made Pregabalin.
There is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 400,000 every year. Therefore, Pregabalin has a bright prospect in China.
– Development environment of Chinese Pregabalin market
– Governmental approval of Pregabalin in China
– Prices of Pregabalin in China
– Major Pregabalin manufacturers in China
– Factors influencing the development of Chinese Pregabalin market
– Prospects of Chinese Pregabalin market